Drug Interactions between apomorphine and Teveten
This report displays the potential drug interactions for the following 2 drugs:
- apomorphine
- Teveten (eprosartan)
Interactions between your drugs
eprosartan apomorphine
Applies to: Teveten (eprosartan) and apomorphine
MONITOR CLOSELY: Apomorphine may potentiate the hypotensive effect of vasodilators and antihypertensive agents. Apomorphine alone has been associated with orthostatic hypotension, hypotension, syncope, and dose-dependent decreases in systolic and diastolic blood pressure. In clinical studies of the subcutaneous formulation of apomorphine in patients with advanced Parkinson's disease, hypotension (10% vs 4%), myocardial infarction (3% vs. 1%), serious pneumonia (5% vs. 3%), serious falls (9% vs. 3%), and bone and joint injuries (6% vs. 2%) were experienced more commonly in patients receiving concomitant antihypertensive medications or vasodilators (n=94) compared to those not receiving these medications (n=456). Some of these events may be related to the increased incidence of hypotension.
MANAGEMENT: Caution and close monitoring for altered efficacy and safety are recommended if patients receive apomorphine with an antihypertensive agent or vasodilator. Some authorities consider the combination of subcutaneous apomorphine with antihypertensive medications or vasodilators to be contraindicated due to a lack of data from studies that systematically evaluated the potential interaction between apomorphine and these agents. Patients should be made aware of the possible side effects (e.g., dizziness, lightheadedness, orthostasis) and be cautioned about driving, operating machinery, or performing other hazardous tasks. They should also be advised to avoid rising abruptly from a sitting or recumbent position and to contact their physician if they experience symptoms of hypotension such as dizziness, lightheadedness, or fainting.
References
- (2004) "Product Information. Apokyn (apomorphine)." Mylan Pharmaceuticals Inc
- (2022) "Product Information. Apokyn (apomorphine)." US WorldMeds LLC
- (2022) "Product Information. Kynmobi (apomorphine)." Sunovion Pharmaceuticals Inc
- (2023) "Product Information. Movapo (apomorphine)." Paladin Labs Inc, 2.0
- (2022) "Product Information. Kynmobi (apomorphine)." Sunovion Pharmaceuticals Canada Inc
- (2024) "Product Information. Dacepton (apomorphine)." Ever Pharma UK Ltd
- (2024) "Product Information. aPomine Intermittent (apomorphine)." Pfizer Australia Pty Ltd, 1.1
- (2024) "Product Information. Movapo (apomorphine)." Stada Pharmaceuticals Australia Pty Ltd
Drug and food interactions
eprosartan food
Applies to: Teveten (eprosartan)
GENERALLY AVOID: Moderate-to-high dietary intake of potassium, especially salt substitutes, may increase the risk of hyperkalemia in some patients who are using angiotensin II receptor blockers (ARBs). ARBs can promote hyperkalemia through inhibition of angiotensin II-induced aldosterone secretion. Patients with diabetes, heart failure, dehydration, or renal insufficiency have a greater risk of developing hyperkalemia.
MANAGEMENT: Patients should receive dietary counseling and be advised to not use potassium-containing salt substitutes or over-the-counter potassium supplements without consulting their physician. If salt substitutes are used concurrently, regular monitoring of serum potassium levels is recommended. Patients should also be advised to seek medical attention if they experience symptoms of hyperkalemia such as weakness, irregular heartbeat, confusion, tingling of the extremities, or feelings of heaviness in the legs.
References
- (2001) "Product Information. Cozaar (losartan)." Merck & Co., Inc
- (2001) "Product Information. Diovan (valsartan)." Novartis Pharmaceuticals
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.